GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GSK (NYSE:GSK) reported on Thursday positive ... The drugmaker had earlier reported positive efficacy results from DREAMM-7, another phase III head-to-head trial evaluating belantamab mafodotin ...

Now, the new data suggests GSK could start to get it at least partially back on track, with some analysts predicting $1.5 billion or more in sales if approved on the strength of the DREAMM-7 and ...